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Background: Recent studies suggest hat nitric oxide is important in the 
pathogenesis of ischemic brain injury and also has a role in controlling 
cerebrovascular tone. This study examines the net effects of nitric oxide on 
cerebral metabolic recovery after deep hypothermic circulatory ar est. Meth- 
ods: Two-week-old piglets were supported by cardiopulmonary b pass and 
cooled to 15 ° C followed by I hour of deep hypothermic circulatory arrest, 45 
minutes of reperfusion and rewarming, and then 3 hours of normothermic 
perfusion. Groups of 10 piglets received one of four treatments before bypass: 
L-nitro-arginine methyl ester, inhibitor of nitric oxide synthesis, 10 mg/kg 
intravenously; L-arginine, to enhance nitric oxide synthesis, 30 mg/kg intrave- 
nously before bypass and then 10 mg/kg per minute during the first hour of 
reperfusion; a combination of L-nitro-arginine methyl ester plus L-arginine at 
these same doses; and no pretreatment (controls). Cerebral high-energy 
phosphates and pH were measured by magnetic resonance spectroscopy in half 
the animals. Cerebral blood flow, metabolic rates for oxygen and glucose, and 
the oxidation/reduction state of cytochrome aa3 and oxygenated and deoxygen- 
ated hemoglobin measured by near-infrared spectroscopy were assessed in the 
other half of the piglets. Results: L-nitro.arginine methyl ester significantly 
increased cerebral vascular esistance and markedly reduced recovery of 
high-energy phosphates, pH, and oxidation state of cytochrome aa3. L-arginine 
increased cerebral blood flow, cerebral glucose and oxygen consumption, and 
recovery of cytochrome aa3 oxidation and high-energy phosphates. L-Arginine 
did not reverse completely the effects of L-nitro-arginine methyl ester on 
cerebral metabolic recovery. Conclusion: In a piglet model of deep hypothermic 
circulatory arrest, ~nitro-arginine methyl ester has a deleterious effect and 
L-arginine has a beneficial effect on cerebral metabolic recovery. The deleteri- 
ous metabolic effects of L-nitro-arginine methyl ester are only partially reversed 
by L-arginine. This fact suggests that there may be mechanisms in addition 
to inhibition of nitric oxide synthesis contributing to the neurotoxicity of 
L-nitro-arginine methyl ester in this model. (J Thorac Cardiovasc Surg 
1996;112:698-707) 
N itric oxide plays important roles in the control of vascular tone in the brain, as well as neurotrans- 
mitter and second messenger roles both intraneuro- 
nally and interneuronally. 1' 2Recent studies suggest 
that nitric oxide affects cerebral vasodilation under 
conditions uch as hypoxia and seizures and after 
ischemia,1, 3 as well as having a physiologic role in 
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the regulation of cerebral blood flow. 4-6 Results of 
in vitro cell studies 7' s and studies with transgenic 
mice lacking neuronal nitric oxide synthase 9 suggest 
that nitric oxide also contributes to the pathogenesis 
of cerebral ischemic damage. In vivo studies also 
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suggest a contribution of nitric oxide to perinatal 
ischemic brain damage. 1°' 11 
Cardiopulmonary bypass (CPB) and deep hypo- 
thermic circulatory arrest (DHCA) are applied clin- 
ically in neonates and infants to facilitate repair of 
congenital heart defects. Clinical studies have dem- 
onstrated permanent neurodevelopmental sequelae 
of the technique. 12 Because deep hypothermia is 
dependent on adequate cerebral blood flow for 
homogeneous brain cooling and rewarming and 
because nitric oxide is a potent cerebrovascular 
dilator in addition to possibly being neurotoxic, we 
have studied the net effects of nitric oxide in our 
piglet model of DHCA. The experiments used N- 
nitro-L-arginine methyl ester (L-NAME) to inhibit 
NO synthesis and L-arginine to enhance its synthe- 
sis. L-NAME is an arginine analog that readily 
crosses the blood-brain barrier and inhibits nitric 
oxide synthase, a group of isoenzymes that catalyze 
the synthesis of nitric oxide from L-arginine. 13' 14 
Administration of L-arginine enhances nitric oxide 
synthesis. Therefore administration of L-NAME and 
L-arginine concurrently allows confirmation that the 
effects observed after L-NAME administration are 
entirely due to inhibition of nitric oxide synthase. 
Material and methods 
Animals. Forty Yorkshire piglets, 12 to 16 days old 
(mean 14 days) and 2.2 to 4.7 kg body weight (mean 3.9 
kg) were studied (Parson's Livestock, Hadley, Mass.). All 
studies were performed incompliance with the "Principles 
of Laboratory Animal Care" formulated by the National 
Society for Medical Research and the "Guide for the Care 
and Use of Laboratory Animals" prepared by the Na- 
tional Academy of Science and published by the National 
Institutes of Health (NIH Publication No. 86-23, revised 
in 1985). 
Surgical preparation. Details of the surgical prepara- 
tion and perfusion protocol have been described previous- 
ly.15, 16 The piglets were anesthetized with an intraperito- 
heal injection of methohexital (40 mg/kg), tracheally 
intubated, and their lungs ventilated with 100% oxygen to 
achieve an arterial carbon dioxide tension between 35 and 
45 mm Hg. Venous and arterial catheters were inserted 
through the femoral vein and artery into the thoracic vena 
eava and aorta. Anesthesia was maintained with continu- 
ous intravenous infusions of fentanyl 25 /xg/kg per hour 
and pancuronium 0.1 mg/kg per hour after initial bolus 
injections. Temperature was monitored throughout the 
study by rectal and nasopharyngeal thermistors. Before 
CPB the temperature was maintained above 35 ° C with a 
heating lamp. Heart rate and blood pressure were moni- 
tored continuously. A bladder catheter was placed to 
monitor urine output. 
The heart was exposed through a median sternotomy 
and the bypass cannulas were placed in the ascending 
aorta and right atrium. The piglet was given heparin (300 
IU/kg) and a 5F catheter was inserted through the right 
internal jugular vein to above the jugular bulb. CPB was 
then begun. An electromagnetic flow probe (Nihon Koh- 
den, Tokyo, Japan) was placed in the arterial perfusion 
circuit to verify the pump flow. The pump circuit was 
primed with 400 ml of 2-day-old homologous blood and 
350 ml of Normosol-R solution pH 7.4 (Abbott Labora- 
tories, North Chicago, Ill.) to achieve a hematocrit value 
of 20% to 25%. Methylprednisolone 30 mg/kg, cephazolin 
sodium 25 mg/kg, and sodium bicarbonate (pH 7.4) were 
added to the prime. The perfusate temperature was 
controlled by the heat exchanger with the oxygenator and 
a circulating water bath. During cooling, ice water was 
circulated in the water bath. 
Perfusion protocol. CPB flow was set at 150 ml/kg per 
minute calibrated at a perfusate temperature of 37 ° C. 
Cooling of the perfusate resulted in a 15% to 20% 
decrease in blood flow measured by the electromagnetic 
flowmeter. (This is most likely related to the change in 
compliance of the tubing in the pump-head raceway that 
occurs when the perfusate is cooled.) The alpha-stat 
strategy was used so that, as measured at 37 ° C, pH was 
maintained at 7.40 by adjusting the flow of 100% oxy- 
gen. a7 The piglet was perfused for 20 minutes at normo- 
thermia (37°C arterial temperature) to stabilize body 
temperature. Then the perfusate was cooled to an arterial 
temperature of 14 ° C. Ice packs were placed around the 
head throughout the cooling and circulatory arrest peri- 
ods. After 30 minutes of cooling, when nasopharyngeal 
temperature was 14.0 ° to 15.0 °C, perfusion was stopped 
for 1 hour. Repeffusion was begun at 150 ml/kg per 
minute with the perfusate at 20 ° C. After 45 minutes of 
reperfusion, by which time normothermia had been 
achieved, ventilation was restarted. Pump perfusion was 
continued for 3 hours with the perfusate temperature at
37 ° C. During this 3-hour period of peffusion, cardiac 
pulsatile assistance was achieved by raising central venous 
pressure minimally (<5 mm Hg). At the end of each study 
the animal was put to death by injection of Somelethal 
solution 1 ml/4 kg (J. A. Webster, Inc., Leominster, Mass.) 
and potassium chloride into the circuit. 
Blood flow measurements. The baseline regional blood 
flow to the brain and other organs was measured by the 
radioactive microsphere technique 20 minutes after the 
initiation of CPB (normothermic baseline) and reflects 
the hemodilution of CPB, as well as any flow changes that 
may have resulted from the nonpulsatile nature of flow 
during CPB. Additional measurements were made 30 
minutes after onset of cooling (at the end of hypothermic 
perfusion) and 15, 45, and 225 minutes after reperfusion 
after the 1-hour period of DHCA. 18 Microspheres (15/xm 
in diameter) labeled with the isotopes iodine 125, cerium 
141, tin 113, strontium 85, or scandium 46 were suspended 
in 0.5 ml of 10% dextran and injected into a side port on 
the arterial tubing. Each injection contained about 2.5 x 
106 microspheres. Blood (5 ml) was withdrawn at a 
constant rate by syringe pump from the thoracic aorta 
catheter during and until 30 seconds after the microsphere 
injection. At the termination of the experiment, the brain, 
heart, lungs, kidneys, liver, adrenal glands, and intestines 
were removed and weighed. The brain was divided into 
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Table  I. Blood gases, hematocrit values, and nasopharyngeal temperatures (NP temp) in piglets receiving 
c-NAME, L-arginine (ARG), or L-NAME plus L-arginine (N+A) as described in Methods; control animals 
received neither agent 
/~efore 
Parameter Group bypass NT HT RP(O) RP(15) NT(O) NT(180) 
Arterial pH Control 7.48 +_ 0.02 7.41 _+ 0.02 7.39 + 0.02 7.43 _+ 0.03 7.41 ± 0.02 7.40 ± 0.02 
L-NAME 7.46 _+ 0.01 7.38 ± 0.02 7.37 _+ 0.02 7.37 ± 0.02 7.37 _+ 0.01 7.36 + 0.01 
ARG 7.45 _+ 0.03 7.40 + 0.02 7.43 _+ 0.03 7.43 + 0.02 7.40 _+ 0.02 7.36 + 0.03 
N+A 7.43 +_ 0.02 7.37 ± 0.01 7.37 ± 0.02 7.39 ± 0.01 7.38 _+ 0.01 7.39 + 0.02 
Arterial carbon dioxide Control 38.2 + 1.1 44.0 _+ 1.3 43.9 _+ 1.1 39.6 + 1.6 43.2 _+ 1.0 43.0 ± 1.0 
tension (mm Hg) L-NAME 41.4 + 1.9 42.5 _+ 1.1 40.7 _+ 1.1 40.7 ± 1.1 42.7 _+ 0.8 42.7 + 1.4 
ARG 38.8 ± 2.8 44.2 ± 2.0 42.1 ± 1.4 39.4 ± 1.9 40.t _+ 1.2 40.5 ± 1.1 
N+A 37.9 ± 0.7 45.8 _+ 1.2 42.0 _+ 1.2 40.2 _+ 1.5 41.7 _+ 0.8 44.1 + 0.8 
Arterial oxygen tension Control 522 ± 54 304 ± 33 764 _+ 64 335 _+ 58 372 _+ 44 431 ± 37 
(ram Hg) L-NAME 398 ± 59 402 ± 46 573 _+ 54 399 ± 33 345 _+ 43 383 ± 42 
ARG 438 + 23 289 -+ 72 830 _+ 45 316 ± 44 341 ± 43 380 ± 28 
N+A 430 _+ 44 271 ± 51 694 ± 49 268 ± 43 317 _+ 50 332 _+ 11 
Hematocrit value (%) Control 33.7 _+ 1.7 25.4 ± 0.6 23.4 ± 1.1 23.8 _+ 0.6 24.0 ± 0.9 24.0 ± 1.0 
L-NAME 33.3 ± 0.9 25.2 + 1.0 23.5 ± 0.8 22.6 _+ 0.6 23.0 ± 0.7 22.4 ± 0.8 
ARG 30.6 ± 1.5 24.5 ± 1.0 23.5 ± 1.1 23.6 _+ 0.6 23.5 ± 0.6 23.6 _+ 0.8 
N+A 32.0 + 0.8 26.8 ± 0.9 24.0 ± 0.4 23.8 ± 0.7 23.5 ± 1.1 23.6 _+ 1.4 
NP temp (°C) Control 36.8 ± 0.6 36.6 _+ 0.7 14.8 _+ 0.3 17.9 _+ 0.5 28.0 ± 0.9 36.2 _+ 0.9 37.4 _+ 0.2 
L-NAME 36.7 ± 0.1 36.6 _+ 0.4 14.7 _+ 0.6 17.1 _+ 0.8 28.1 + 0.9 36.1 _+ 0.4 36.9 ± 0.2 
ARG 36.3 ± 0.3 36.6 ± 0.3 14.0 _+ 0.3 16.6 _+ 0.5 30.0 ± 1.2 36.1 ± 0.4 37.1 _+ 0.2 
N+A 36.5 _+ 0.4 37.1 ± 0.3 14.1 _+ 0.3 16.6 _+ 0.7 28.7 ± 1.2 36.9 ± 0.3 37.3 _+ 0.2 
Rectal temp (°C) Control 36.1 ± 0.5 36.7 ± 0.6 17.5 _+ 0.7 23.1 _+ 0.8 30.9 _+ 0.7 35.1 ± 0.3 37.2 ± 0.2 
L-NAME 36.5 + 0.3 36.8 _+ 0.3 19.2 + 0.9 23.0 ± 0.6 29.5 ± 0.8 34.5 _+ 0.6 36.8 _+ 0.3 
ARG 36.7 ± 0.3 37.0 ± 0.3 17.3 ÷ 0.8 23.1 ± 0.5 30.9 _+ 1.3 34.3 _+ 0.9 37.5 _+ 0.3 
N+A 36.8 ± 0.4 37.3 ± 0.2 16.6 ± 0.6 22.1 ± 0.5 31.9 + 0.3 35.0 ± 0.8 37.0 _+ 0.3 
Before bypass, Before initiation of CPB; NT, after 20 minutes of normothermic perfusion; HT, at the end of hypothermic perfusion; RP(0), immediately before 
reperfusion; RP(15), 15 minutes after beginning reperfusion; NT(O), after 45 minutes of reperfusion a d warming; NT(180), normothermia for180 minutes. 
Data are mean -+ standard deviation. There were no significant differences between groups. 
five parts: the cerebral hemispheres, basal ganglia, mid- 
brain, cerebellum, and brain stem (pons and medulla 
oblongata). The organs and blood samples were dissolved 
in 2N potassium hydroxide-methanol s lution and the 
radioactivity was counted (Compugamma 1282, LKB In- 
struments Inc., Wallac, Finland). Blood flows were calcu- 
lated from the rate of withdrawal of reference blood and 
the ratio of radioactivities in the tissues and the reference 
blood. 
Metabolic measurements. Blood gas tensions, pH, he- 
moglobin, plasma glucose, and lactate concentrations 
were measured in arterial and jugular venous blood 
before CPB and after each microsphere injection. Blood 
gases and hemoglobin were measured with a blood gas 
analyzer (Stat Profile 5, NOVA Biomedical, Waltham, 
Mass.). Plasma glucose and lactate concentrations were 
determined by the glucose oxidase method and enzymatic 
ftuorometric micromethod, respectively. Cerebral oxygen 
consumption and glucose consumption were calculated 
from the total cerebral blood flow and the differences 
between the arterial and internal jugular venous oxygen 
and glucose concentrations. The oxygen content was 
calculated by the formula: Oxygen = 1.34 × Hemoglobin 
(gm/dl) × Oxygen saturation + 0.003 × Oxygen tension. 
Magnetic resonance spectroscopy. Piglets studied by 
phosphorus 31-nuclear magnetic resonance spectroscopy 
underwent he same surgical procedure and CPB as 
described earlier. All studies were performed in an Oxford 
40 cm horizontal bore superconducting 4.7 T magnet 
(Oxford Research Systems, Oxford, United Kingdom) at 
the Francis Bitter Magnet Laboratory (Massachusetts 
Institute of Technology). A 3.0 cm diameter copper 
surface coil was sutured to the scalp centered on the skull 
behind the supraorbital ridges. After placement, he coil 
was matched and tuned to the phosphorus frequency. 
Spectra were acquired in the Fourier transform mode on 
a custom-built spectrometer with an optimized excitation 
pulse of 100/zsec. Each spectrum was the average of 128 
acquisitions with a 5-second interpulse interval. The spec- 
tral width was 4000 Hz. Relative concentrations of inor- 
ganic phosphate, creatine phosphate, and nucleoside 
triphosphate were determined from peak areas obtained 
by Lorentzian curve fitting and peak integration. Changes 
in adenosine triphosphate (ATP) were assessed from 
changes in/3-nucleoside triphosphate peak, of which ATP 
contributes 60% to 70%. 19 The inorganic phosphate, 
creatine phosphate, and nucleoside triphosphate changes 
are reported as percentages of the full-flow normothermic 
values after 20 minutes of CPB. The intracellular brain pH 
was calculated from the chemical shift of the inorganic 
phosphate peak relative to the creatine phosphate peak. 2° 
Near-infrared spectroscopy. The near-infrared spec- 
trometer used in this study was the NIRO-5 spectrometer 
(Hamamatsu Photonics KK, Hamamatsu, Japan). A small 
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Fig. 1. Mean arterial blood pressures before and after deep hypothermic irculatory arrest in piglets 
treated with L-NAME, L-arginine (ARG), or L-NAME plus L-arginine (NAME+ARG) are compared with 
results in untreated control piglets. The results are the mean _+ standard eviation for 10 animals in each 
group. The labeled time points are Pre (before placement on CPB); NT (normothermia before cooling); HT 
(after cooling to 15 ° C); RP15 (15 minutes after beginning the postarrest reperfusion); NTO (45 minutes 
after beginning reperfusion when the temperature has reached 36 ° to 37 ° C); and NT180 (after 3 hours of 
normothermic reperfusion). *Difference from controls with a significance ofp < 0.05. 
area of scalp was excised and plastic collars were glued 
directly to the skull. Fiberoptic optodes for transmission 
of laser light of near-infrared wavelengths and for photon 
detection were secured to the collars with plastic screws. 
The optodes were placed 3.0 to 3.5 cm apart in the coronal 
plane. The animal was then positioned supine with the 
head placed on a pillow designed to protect he optodes. 
Concentration changes in brain oxygenated hemoglo- 
bin, reduced hemoglobin, and cytochrome aa3 were col- 
lected continuously from after induction of anesthesia to 
the end of experiment. Light was transmitted through the 
skull at four wavelengths: 776 nm, 828 nm, 848 nm, and 
913 nm. Light was transmitted in sequential pulses at 
these frequencies. Photons enlerging from the sample 
were collected by the second optode and counted by a 
photomultiplier tube. The difference between transmitted 
and received light intensity at each wavelength was used to 
determine optical density changes. Computer calculations 
based on chromophore absorption spectra then deter- 
mined changes in oxygenated hemoglobin, reduced hemo- 
globin, and cytochrome aa3 concentrations in (tool/ 
L) • dpf according to the Beer-Lambert law. 21-23 The term 
dpf is the differential pathlength factor, which corrects the 
measured optode separation distance for light scattering 
within the sample. Because the dpf for piglet brain is not 
known, results are expressed in concentration 
change, dpf. The dpf was assumed to be constant in each 
experiment. Near-infrared spectroscopy measurements 
were made with a sampling interval of 30 seconds. 
Experimental design. Four groups were defined ac- 
cording to treatment before initiation of CPB. Ten piglets 
received L-NAME 10 mg/kg intravenously before initia- 
tion of CPB. A second group of 10 animals received 
L-arginine 30 mg/kg before CPB and then continuous 
intravenous infusion of arginin~e at a dose of 10 mg/kg per 
minute during the first hour of reperfusion. A third group 
of 10 animals received L-NAME plus L-arginine at the 
same doses and times. The control group of 10 piglets 
received neither of these compounds. In 20 piglets (five 
from each group) cerebral metabolic rates were deter- 
mined by arteriovenous differences in oxygen and glucose, 
blood flows by radioactive microspheres, and oxygenation 
by near-infrared spectroscopy. The remaining five animals 
from each group underwent the same surgical and bypass 
procedures while being studied by phosphorus 31-nuclear 
magnetic resonance spectroscopy. Only measurements 
made at the end of normothermic perfusion, the end of 
cooling, and 15, 45, and 225 minutes after reperfusion 
were compared. Results are reported as a percentage of 
the measurements at the end of the initial normothermic 
CPB. 
Statistics. All values are reported as mean _+ standard 
error of the mean. A statistical analysis system (SPSS, 
SPSS Inc., Chicago, Ill.) was used for all analyses. 
Repeated-measures analysis of variance and Student- 
Newman-Keuls test were used to detect differences between 
groups. Ap  value less than 0.05 was considered significant. 
Results 
Baseline conditions. The initial conditions of pig- 
lets including blood gases, hematocrit values, and 
body temperatures were the same in all groups 
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Fig. 2. Cerebrovascular resistance (A) and cerebral blood flows (B) before and after DHCA in piglets 
treated with L-NAME, L-arginine (ARG), or L-NAME plus L-arginine (NAME+ARG) are compared with 
results in untreated control piglets. The results are the mean _+ standard eviation for five animals in each 
group. Blood flows were measured by labeled microspheres as described in Methods. The time points are 
described in Fig. 1. *Difference from control animals with a significance value ofp < 0.05. 
(Table I). Unless noted otherwise, all blood gas 
values are reported as being measured at 37°C 
without body temperature correction. When CPB 
was begun, hematocrit values decreased in all 
groups and reflected hemodilution by the pump 
prime. There were no differences in blood gas 
values, hematocrit values, and temperatures among 
the four groups throughout the experiment. 
Mean arterial pressures and cerebral blood flows. 
Systemic arterial pressures were the same in control 
animals and in the three experimental groups before 
the drugs were administered (Fig. 1). After 
L-NAME, arterial pressures were significantly 
higher than in control animals. Blood pressures in 
piglets receiving L-NAME plus arginine were inter- 
mediate between L-NAME and control groups. Af- 
ter the hypothermic period, the arterial pressures in 
the two L-NAME groups remained higher than 
those in control animals. Blood pressures in the 
arginine-treated piglets and control animals were 
the same throughout the experiments. During the 
reperfusion period, the arterial pressures increased 
progressively above pre-CPB values in all four 
groups. 
The total systemic blood flow calculated from the 
radioactivity in each microsphere injection and the 
reference blood correlated well with the pump flow 
measured by the electromagnetic flowmeter (y = 
0.98~ - 7.3, r = 0.945, p = 0.001). Cerebrovascular 
resistance (Fig. 2, A) was increased at baseline during 
normothermic CPB after administration f L-NAME 
and was markedly elevated uring cooling. Cerebral 
blood flow did not decrease, however, the reasons 
being the generalized increase in systemic blood pres- 
sure after L-NAME administration a d the decrease in 
viscosity associated with the hemodilution ofCPB. The 
piglets treated with I, arginine had higher cerebral 
blood flows than did the control animals (Table II, Fig. 
2, B). The cerebral blood flows were higher in this 
group before hypothermia and in the early reperfusion 
measurements. The c-arginine-treated piglets had 
higher blood flows than the control piglets in the 
cerebral hemispheres (p < 0.025), basal ganglia (p < 
0.025), and the midbrain (p < 0.05). Administration of
L-arginine with L-NAME tended to reverse the va- 
soconconstrictive effect of L-NAME at baseline but not 
subsequently (Table II and Fig 2). In all groups, blood 
flow remained epressed after 15 and 45 minutes of 
reperfusion and rewarming. However, by 225 minutes 
cerebral blood flow exceeded the baseline in all groups 
except the arginine-treated piglets, in which it returned 
to (its elevated) baseline. Changes in regional brain 
blood flows were similar to those in global flows (not 
shown). 
Cerebral high-energy phosphates and intracellu- 
lar pH. Administration of L-NAME and initiation 
of normothermic CPB did not affect nucleoside 
triphosphate and creatine phosphate concentrations 
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Fig. 3. The phosphorus 31-nuclear magnetic resonance spectroscopic measurements of cerebral nucleo- 
side triphosphate (A), phosphocreatine (B), and intracellular pH (C) before and after DHCA in piglets 
treated with L-NAME, L-arginine (ARG), or L-NAME plus L-arginine (NAME+ARG) are compared with 
results in untreated control piglets. Details of the NMR experiments are described inMethods. The results 
are the mean +- standard eviation for five animals in each group expressed as a percent of the 
prehypothermic values (NT). The time points are defined in Fig. 1. *Significance value ofp < 0.05, shown 
only for the designated time points. 
or pH. Both nucleoside triphosphate and creatine 
phosphate increased whereas pH became more al- 
kaline during cooling in control and L-arginine 
groups (Fig. 3). The L-NAME-treated group 
showed no increase in nucleoside triphosphate or 
creatine phosphate during cooling. The intracellular 
pH became alkaline during cooling in the L-NAME- 
treated animals, but less alkaline than in control 
animals. Except for nucleoside triphosphate, all 
values were intermediate in the animals treated with 
L-NAME plus L-arginine. 
Recoveries of high-energy compounds and of 
intracellular pH were markedly reduced in the 
brains of the L-NAME-treated group compared 
with recoveries in the control group (Fig. 3). The 
percent recovery of nucleoside triphosphate was 
about half the control value in the L-NAME- 
treated animals. Recoveries of creatine phosphate 
and intracellular pH after reperfusion were simi- 
larly reduced in L-NAME-treated animals. The 
intracellular pH was significantly more acidic after 
reperfusion i animals treated with L-NAME than 
in control animals. 
The creatine phosphate and nucleoside triphos- 
phate concentrations and intracellular pH were 
the same in arginine-treated piglets and control 
piglets before and during cooling (Fig. 3). The 
changes in nucleoside triphosphate, creatine 
phosphate, and pH during cooling were the same 
in piglets treated with L-arginine plus L-NAME as 
in those treated with L-NAME. After DHCA, 
recoveries of creatine phosphate, nucleoside 
triphosphate, and intracellular pH were greater 
and occurred sooner in L-arginine-treated piglets 
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Table II. Baseline values for blood flows~and glucose and oxygen consumptions in brains of piglets rece&ing 
c-NAME; L-arginine (ARG), or L-NAME +L-arginine (N+A), as described in Methods; control animals 
received neither agent 
Parameters Control L-NAME ARG N +A 
Cerebral blood flow (ml/min/100 gm tissue) 35.6 _+ 2.1 33.8 _+ 2.5 62.4 _+ 8.8* 39.1 _+ 2.7 
CMR-O2 (/zl/min/100 gm tissue) 1.47 _+ 0.14 1.31 _+ 0.17 2.97 _+ 0.43* 2.16 + 0.14 
CMR-glucose (mg/min/100 gm tissue) 6.14 _+ 0.72 5.39 _+ 1.26 13.66 _+ 0.72* 9.66 -+ 1.69 
Systemic oxygen consumption (/zl/min/kg) 4.30 _+ 0.32 5.34 _+ 0.39 7.42 + 0.69* 6.00 _+ 0.62 
Systemic lactate level (mmol/L) 3.24 _+ 0.38 3.20 _+ 0.26 3.70 +- 0.35 4.25 _+ 0.60 
Regional blood flow (ml/min/100 gm tissue) 
Heart 176.9 _+ 18.7 210.5 _+ 12.6 325.9 _+ 46.8* 258.7 _+ 39.4 
Kidney 119.3 -+ 17.5 92.3 + 20.6 120.2 _+ 29.2 76.9 - 12.5 
Liver (hepatic arterial) 70.0 _+ 14.5 87.2 _+ 25.0 63.4 _+ 23.7 61.1 _+ 10.4 
Intestine 47.8 _+ 5.2 92.2 _+ 22.2 128.7 _+ 31.9" 76.2 _+ 5.1 
Lung (bronchial) 8.8 _+ 2.8 9.9 _+ 2.9 11.8 _+ 3.0 7.2 _+ 1.6 
Adrenal glands 469.6 _+ 55.3 250.3 _+ 22.6 608.4 _+ 84.5 459.4 _+ 95.1 
Carcass 11.5 _+ 0.3 14.0 _+ 0.9 19.0 + 2.2 14.4 _+ 0.45 
CMR, Cerebral metabolic rate. Data are mean -+ standard eviation. 
*p < 0.05 versus control animals. 
than in control animals. In contrast, recovery of 
brain creatine phosphate and nucleoside triphos- 
phate concentrations and intracellular pH was 
worse in piglets treated with L-arginine plus L- 
NAME than in control animals, similar to the 
effects of L-NAME alone. Immediately after nor- 
mothermic reperfusion, concentrations of brain 
high-energy phosphates and pH in the L-arginine 
plus L-NAME group transiently increased com- 
pared with values in the animals treated with 
L-NAME alone. 
Cerebral metabolic rates for oxygen and glucose. 
At all time points there were no differences in 
cerebral oxygen or glucose consumption between 
L-NAME-treated piglets and control piglets (Fig. 4). 
Cooling was associated with decreases in cerebral 
oxygen and glucose consumption to approximately 
15% of baseline. Like cerebral blood flow, cerebral 
oxygen and glucose consumption remained de- 
pressed uring early reperfusion, but after 180 min- 
utes of normothermic reperfusion baseline values 
were regained in both groups. Blood lactate levels 
and systemic oxygen consumption were increased 
during the recovery period in the L-NAME and 
control groups (results not shown). 
In contrast, both cerebral oxygen and glucose 
consumption were higher in the L-arginine-treated 
animals than in control or L-NAME-treated piglets 
(Fig. 4). These differences were significant only 
before hypothermia, but increased metabolic rates 
were present hroughout the experiment. The re- 
sults in the L-NAME plus L-arginine group tended to 
be intermediate between results in the L-NAME and 
in the L-arginine groups (Fig. 4). 
Near-infrared spectroscopy. Administration of L- 
NAME or L-arginine did not affect the pre-CPB 
values of oxygenated hemoglobin, reduced hemo- 
globin, or redox state of cytochrome aa3 (Fig. 5). 
The initiation of CPB was associated with hemodi- 
lution, causing falls in oxygenated hemoglobin and 
reduced hemoglobin that did not stabilize until 12 
minutes after the onset of CPB. Cytochrome aa3 
became slightly reduced uring cooling in all groups. 
During DHCA there was a further decline in oxida- 
tion of cytochrome aa3. 
During reperfusion cytochrome aa3 oxidation 
gradually returned toward baseline in control ani- 
mals but remained reduced in the L-NAME-treated 
group. The differences between the cytochrome aa3 
oxidation/reduction state in the L-NAME-treated 
group and the control animals became highly signif- 
icant at 180 minutes of normothermic reperfusion. 
The pigs treated with L-arginine had higher cyto- 
chrome aa3 oxidation states than did control ani- 
mals during reperfusion, with full recovery in both 
groups (Fig. 5). However, like the L-NAME-treated 
piglets, the L-NAME plus L-arginine group showed 
no recovery of cytochrome aa3 oxidation state dur- 
ing reperfusion. 
Oxygenated hemoglobin increased uring cooling 
in all groups. After the onset of DHCA there was 
progressive desaturation. The oxygenated hemoglo- 
bin and the reduced hemoglobin values were the 
same in all groups both during and after DHCA. 
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Fig. 4. Rates of cerebral glucose (A) and oxygen (B) consumptions before and after DHCA in piglets 
treated with L-NAME, L-arginine (ARG), or L-NAME plus L-arginine (NAME+ARG) are compared with 
results in control piglets receiving no treatment. Details of the metabolic rate calculations are given in 
Methods. The results are the means _+ standard eviation for five piglets in each group. The time points are 
given with Fig. 1. *Significance value ofp < 0.05. 
The oxygenated hemoglobin level was increased 
above baseline whereas the reduced hemoglobin 
value was at baseline after 180 minutes of normo- 
thermic reperfusion. Thus cerebral blood volume 
(oxygenated hemoglobin plus reduced hemoglobin) 
increased after DHCA comparably in all the treat- 
ment groups and the control group. 
Discussion 
This study demonstrates that L-NAME inhibition 
of nitric oxide synthesis increases cerebral vascular 
resistance during CPB and markedly reduces recov- 
ery of cerebral high-energy phosphates, pH, and 
cytochrome aa3 after DHCA. Conversely, during 
normothermic CPB L-arginine increases cerebral 
blood flow, as well as cerebral glucose and oxygen 
consumption, and it increases recovery of cyto- 
chrome aa3 and high-energy phosphates after circu- 
latory arrest. Thus in the specific setting of DHCA 
any deleterious effects of nitric oxide synthesized 
within neurons appear to be overwhelmed by the 
beneficial vasodilatory effects of nitric oxide synthe- 
sized within endothelial cells. 
The results of this study are consistent with those 
of our previous tudy, in which the effects of two 
different doses of L-NAME on cerebral blood flow 
and metabolism before, during, and after circulatory 
arrest were evaluated. 24 In the previous tudy also, 
L-NAME increased mean blood pressure, cerebral 
vascular resistance, and brain water content and did 
not cause measurable differences in cerebral blood 
flow. Under normal physiologic conditions adminis- 
tration of L-NAME results in decreased cerebral 
blood flow. However, CPB usually results in in- 
creased synthesis of vascular nitric oxideY Further- 
more, the decrease in viscosity related to the he- 
modilution of the pump prime usually contributes to
a marked ecrease in blood pressure at the onset of 
CPB. However, in animals given L-NAME, blood 
pressure increased after the onset of CPB and 
cerebrovascular resistance increased, confirming ef- 
fective inhibition of nitric oxide synthase at the dose 
used. 
The effects of L-arginine in the piglet brain differ 
markedly from those observed with L-NAME. Dur- 
ing CPB L-arginine did not alter the arterial pressure 
but did increase cerebral blood flow. Arginine also 
significantly increased glucose and oxygen consump- 
tion in brain both before and after circulatory arrest. 
The post-DHCA recovery of cytochrome aa3 oxida- 
tion state was faster in arginine-treated piglets than 
control animals, in contrast to the persistent reduc- 
tion seen in the L-NAME-treated piglets. Similarly, 
the phosphorus 31-nuclear magnetic resonance 
studies howed recovery of creatine phosphate and 
nucleoside triphosphate to be significantly greater 
and to occur earlier in the arginine group compared 
with both the L-NAME-treated animals and the 
control animals. 
When the two treatments, L-NAME and L-argi- 
nine, were combined, arginine did not completely 
reverse the L-NAME inhibition of cerebral meta- 
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Fig. 5. Cerebral near-infrared spectroscopic measures of oxidation state of cytochrome aa3 in piglets 
receiving L-NAME, L-arginine (ARG), or L-NAME plus L-arginine (NAME+ARG) are compared with 
results in untreated control piglets. Details of the measurement techniques are given in Methods. The 
results are the mean -+ standard eviation for five piglets in each group. The time points are given with Fig. 
1. *Significance value ofp < 0.05. 
bolic recovery. This may be a dose-related effect. 
For example, the arterial pressures and cerebral 
blood flows in piglets receiving the combined 
treatment were intermediate between the values 
with the individual treatments, consistent with 
competitive inhibition of arginine by L-NAME as a 
nitric oxide synthase substrate. An intermediate 
response also was seen in the oxygen and glucose 
consumptions before and after DHCA. Interest- 
ingly, in contrast, cytochrome aa3 remained severely 
reduced after the DHCA in piglets receiving the 
combined treatment. Similarly, recovery of creatine 
phosphate, nucleoside triphosphate, and intracellular 
pH was comparably depressed in the piglets receMng 
the combined treatment and L-NAME alone. The 
combined treatment did produce an early improve- 
ment of the metabolic recovery, but this effect was 
transient. 
It is not clear why administration of arginine did 
not reverse the effects of L-NAME on cytochrome 
redox state and cerebral high-energy phosphates. 
L-NAME might be uncoupling oxidative phosphor- 
ylation and thus inhibiting ATP synthesis while 
producing a net reduction of the electron transport 
chain. L-NAME may have a direct effect on oxida- 
tive phosphorylation a d ATP synthesis in addition 
to effects on nitric oxide synthesis. Both arginine and 
L-NAME might act as phosphogen precursors as 
analogs of creatine. 
A number of reports have described possible roles 
for nitric oxide in the pathogenesis of cerebral 
ischemic injury. In neuronal culture, nitric oxide 
may participate in N-methyl-D-aspartate-mediated 
cytotoxicity by generating highly toxic free radical 
species.7, s Despite these cytotoxic effects observed 
in vitro, nitric oxide has tissue-sparing effects based 
on antiplatelet, 26 antileukocyte, 27 directly quenching 
superoxide free radicals, 28 and vasodilatory 29 ac- 
tions in vivo within ischemic tissue. Nitric oxide 
donors are neurotoxic if the redox state of the 
medium favors formation of NO- and are neuro- 
protective if the redox milieu favors NO + forma- 
tion. 3° Cell toxicity of nitric oxide also may be 
mediated by peroxynitrite formation, and a neuro- 
protective ffect may be linked to S-nitrosylation of
N-methyl-D-aspartate receptor thiol groups, a pro- 
cess resulting in downregulation f the N-methyl-D- 
aspartate receptor and attenuation of N-methyl-D- 
aspartate-mediated n urotoxicity. 3°'31 
In conclusion, in this clinically relevant model of 
hypothermic global cerebral ischemia, L-NAME has 
a net deleterious effect and L-arginine has a net 
beneficial effect on cerebral metabolic recovery. The 
deleterious metabolic effects of L-NAME are only 
partially reversed by L-arginine, which suggests that 
there may be mechanisms other than inhibition of 
nitric oxide synthesis contributing to the neurotox- 
icity of L-NAME under these conditions. 
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